FDA Recommends Against Currently Available Ovarian Screening Tests


The FDA issued a recommendation against the use of any currently available screening tests for ovarian cancer.

The US Food and Drug Administration (FDA) issued a recommendation against the use of any currently available screening tests for ovarian cancer. The recommendation was directed at both women and at clinicians, who are warned not to recommend or use any screening tests for ovarian cancer in asymptomatic women.

“Despite extensive research and published studies there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a high number of inaccurate results,” the FDA wrote. “However, over the years, numerous companies have marketed tests that claim to screen for and detect ovarian cancer.”

The most commonly used screening test is a CA-125 blood test, with one such tool marketed as the ROCA test (Abcodia Inc). There have been some promising studies with this test, though its effects on mortality have not been dramatic.

In one large study published in the Lancet in March 2016, more than 200,000 postmenopausal women aged 50 to 74 years were randomized to a multimodal screening program using the ROCA test, screening with transvaginal ultrasound, or no screening.

There were 1,282 cases of ovarian cancer over an 11.1-year follow-up period. A proportional hazards model showed a 15% reduction in mortality over years 0 to 14 with the ROCA screening test, but this did not reach significance (P = .10). The ultrasound screening also failed to significantly reduce mortality. There was, however, a significant reduction in death from ovarian cancer with ROCA (P = .021); most of that reduction occurred in years 7 to 14 rather than the first 7 years of screening.

Though this was deemed promising, the FDA pointed out that there remain significant false-positive rates that make the test’s use problematic. In that study, for each ovarian and peritoneal cancer detected by screening, two women in the ROCA group had false-positive surgery.

The FDA’s statement noted that clinicians should “consider referring women at high risk of developing ovarian cancer, including those with BRCA mutations, to a genetic counselor or gynecologic oncologist, or other appropriate health care provider for more specialized care.” The US Preventive Services Task Force is currently updating its ovarian cancer screening recommendations, but in 2012 it also recommended against screening in asymptomatic women.

Related Videos
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content